In the absence of effective antiviral therapies, especially for severe cases of influenza and SASR-CoV-2 infections, several groups of medicines have been identified on the basis of practical medical knowledge that can relieve patients or save their lives (repurposed drugs). There is also a group of non-approved clinical candidates which, after taking into account the benefits for the patient that outweigh the potential risks, is allowed to be treated (referred to as compassionate/emergency used drugs). Regardless of this classification, it should be stressed that these are substances that have never been designed for an ongoing pandemic or acute influenza cases. Based on the current state of knowledge, the applicant proposes a multi-track research project aimed at obtaining optimal antiviral therapy. Approved for the treatment of COVID-19, experimental drug &Amp;ndash; Remdesivir, the action of which is based on the inhibition of RNA-dependent RNA polymerase (RDRP — responsible for virus replication), was in fact originally designed for the treatment of hepatitis C and was then tested for the treatment of Margburg and Ebola haemorrhagic fevers. Based on this therapeutic objective, the Applicant proposes a synthesis of new structural Remdesivir analogues optimised for efficiency, bioavailability, retention and administration. In parallel, based on approved substances: Camostat/Nafamostat, the applicant proposes the synthesis of new analogues with attention to the synergy of anticoagulant activity and inhibitory activity of transmembrane type II serine protease (TMPRSS2). SA.41471(2015/X) Purpose_public_aid: Article: 25 of Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty Urz. EU L 187/1 of 26.06.2014)